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by Marvin A. Schneiderman* and Charles C. Brown*
Three important issues impinge on estimating the risk ofcancer to a population: (1) How can one use
epidemiologic studies on one population to tell us what is likely to happen to other populations? (2) How
can one use nonhuman data (i.e., laboratory experiments) to tell us what is likely to happen to humans?
(3) What reasonable assumptions can be used to guide the logical extension of information from the
laboratory to expectations for man, and what research is needed to support or modify these assumptions?
Four principles currently guide our laboratory-to-man extrapolations: effects in animals, properly qual-
ified, are applicable to man; methods do not now exist to establish a threshold for long-delayed effects
such as cancer; the exposure of experimental animals to high doses is a necessary and valid method of
discovering possible cardnogenic hazards in man; materials should be assessed in terms of human risk
rather than as "safe" or "unsafe."
The risks ofingesting pollutants can be estimated
with data from two sources. Data come from the
laboratory and from the outside world (epidemiol-
ogy). Laboratory studies range from DNA modifi-
cation experiments through mutagenesis studies on
cells in culture, to life-time animal-feeding studies.
The animal studies usually expose relatively few
animals to characterized pollutants at known con-
centrations. Epidemiological studies deal with
human populations. They are sometimes charac-
terized as constructing the analyses of experiments
conducted by nature, involving large numbers of
people. Nature shows no evidence of any formal
training in experiment design, so exposure to the
pollutant in question is commonly uncertain and
more often than not confounded by exposures to
other pollutants.
Both types ofstudy aim to provide information on
the risk to man. Laboratory studies often can pro-
vide precise information on relatively high risks re-
lated to individual pollutants in this or that animal
species, before, during, or after exposure to man.
Epidemiologic studies can provide less precise in-
formation on the risk to man and often require
sophisticated statistics to isolate effects of one pol-
lutant from the effects ofthe other pollutants which
are usually present.
For materials newly introduced into the environ-
ment or to which humans are not yet exposed, the
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only way to assess possible risk to humans is
through laboratory studies. For materials which
may cause cancer, "newly introduced" means
anything more recent than 25 or 30 years ago, be-
cause cancers usually do not appear until 25-30
years after people have been exposed. For materi-
als which have been in the environment longer,
epidemiologic studies are more likely to be useful.
Epidemiology has discovered most of the known
causes of cancer in man. With the improved ability
of the laboratory to discover potentially dangerous
material-and more and more materials entering the
environment-imaginative crosslinking between
laboratory and epidemiologic data has become of
the utmost importance.
Pollutants have many different effects. At one
extreme, they cause cloudless skies to be grey, our
eyes to smart, our noses to run, and the civil au-
thorities to issue airpollution "alerts," about which
the community seems to not know what to do.
While people puzzle about action, the wind
changes, itrains, the skies clear, and we waitforthe
next incident. At the other extreme, the human
health effects of a carcinogen present in the air are
likely to go undetected, particularly if the carcino-
gen produces only a modest increase in the inci-
dence of a common cancer, and if that increase oc-
curs only many years later.
Acute effects are usually quickly perceived and
can often be dealt with in the short term. However,
identification and characterization ofpollutants that
lead to chronic, irreversible, progressive diseases
such as cancer is much more difficult. In addition to
February 1978 115characterizing pollution we must also characterize
populations, because it is necessary to develop risk
estimates for human populations of varied suscep-
tibilities exposed to small concentrations of these
pollutants.
The health problems that pollutants pose involve
two major linked scientific issues. The first lies in
the nature of the health problem itself. Is it an ill-
ness that is reversible, or self-limiting, or easily (or
nearly universally) curable? Or is it an irreversible,
self-perpetuating, hard-to-treat, often fatal illness,
such as cancer? The second scientific issue lies in
whether there is some level of exposure below
which no health damaging effect will occur to any
human. Such a dose level is called a "threshold." If
a threshold for a material or a combination ofmate-
rials can be shown, then a safe level can be easily
set.
For many toxic reactions there is usually good
biological reason to believe that a threshold will
exist. If no clinical illness will occur unless some
large number ofcells is destroyed or damaged, then
if a dose of a material damages or destroys far less
than this number ofcells, no clinical illness will fol-
low, and we can safely say that the dose was below
the threshold-and hence "safe." The problem of
determining whether a threshold does exist is inti-
mately related to the biology ofthe disease process.
If the disease process can be initiated by a single
event, following which the process is self-
sustaining-requiring no further exposure-then
the threshold will be at the level ofthe dose required
to initiate that single event. If there are natural re-
pair mechanisms that can reverse that single event
or keep it from ever becoming self-perpetuating,
and if this repair is complete up to some dose level
where the mechanism is "overwhelmed," then
there will be a threshold at the level just below the
"overwhelming" level. Since it is very likely that
the ability to repair varies from person to person, a
repair-determined threshold in a population will be
the threshold of the most sensitive persons in that
population. Ifthe same repair mechanism must deal
with many materials, each of which contributes to
its being overwhelmed, then it may be necessary to
talk about threshold for added-on materials. An
immediate consequence is that the possible
threshold for these added-on or newer materials
may already be fully consumed by other materials
already present in the real world. If the repair
mechanism is not complete, there will not be a
threshold, and there will be some not as yet well
understood modifications in the dose-response
curves.
Given what is known today about the biology of
cancer, mathematical models ofdose response have
been developed. No single model has captured allof
the scientific community, and the different models
currently being used and a more detailed considera-
tion of threshold will be discussed later.
Because cancer is today believed to be a single
event or multiple-event, self-perpetuating disease
with a long latent period, and with (at present) little
evidence of complete repair, it looks as if we must
rely extensively on predictive techniques-mostly
laboratory techniques-from the subcellular to the
whole animal, whole life-time experimentation. Be-
cause of this need to rely on laboratory predictive
techniques, it is useful to lay out current thinking
about these techniques and to ask if it is reasonable
or unreasonable to rely on them. These can be
stated as a group ofgenerally accepted 'principles."
General Principles
Principle 1
Effects in animals, properly qualified, are appli-
cable to man. All of experimental biology and
medicine makes this assumption. In cancer, this as-
sumption seems thoroughly reasonable, because
cancer in humans and animals is strikingly similar.
Virtually every form of human cancer has an ex-
perimental counterpart, and every form of mul-
ticellular organism is subject to cancer, including
insects, fish, and plants. Despite differences in sus-
ceptibility between different animal species, be-
tween different strains of the same species, and
between individuals of the same strain, car-
cinogenic chemicals nonetheless affect most
species. A considerable body ofdata exists showing
that exposures carcinogenic to animals are likely to
be carcinogenic to humans and vice versa.
The first reported instance of chemical car-
cinogenesis was cancer of the scrotum in chimney
sweeps, observed by the British surgeon, Percival
Pott, in 1775. It took 140 more years to show that a
substance implicated in human cancer was car-
cinogenic in animals. In 1915 Japanese scientists
found that extracts from coal tar cause cancer when
applied to the skin of experimental animals. Since
then, many pure carcinogenic chemicals, including
many isolated from a wide variety of"tars" derived
from incomplete combustion of organic matter,
such as coal, wood, and tobacco, have been shown
to produce cancer. There is little doubt that chemi-
cal products of burning, alone or in combination,
are responsible for the greatly increased incidence
of lung cancer among smokers. With the possible
exception of arsenic and benzene, all known car-
cinogens in man are also carcinogenic in some
species, although not in all that were tested.
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Methods do not now exist to establish a threshold
for long-delayed effects of toxic agents such as
cancer. In classical toxicology, maximal tolerated
(no-effect) doses in humans have been set on the
basis of finding a no-observed-adverse-effect dose
in acute experiments in animals and then dividing
this dose by a "safety factor" of, say, 100, to desig-
nate a "safe" dose in humans. The obvious as-
sumption is that a threshold lies below the no-
observed-effect dose, and certainly above that
dose divided by a safety factor. There is no scien-
tific basis for similar estimation ofa safe dose when
one looks at chronic effects. In addition, the level of
the no-effect-observed dose is strongly dependent
upon the sample size of the experiment. For exam-
ple, if no tumors are obtained in an assay of 100
animals, this implies that at a 95% confidence level
the true incidence ofcancer in this group ofanimals
is less than 5%. Ifwe used 1000 animals for assay at
a single dose and no tumors appeared, we could
only be 95% sure that the true incidence were less
than 0.5%. For a disease such as cancer 0.5% is a
very high risk for a large human population.
There are other problems in relation to animal
experimentation. It is not clear what the operating
characteristics are ofmost test systems. That is, we
do not know how often the system will mislead by
labelling a material as "positive" when it is not a
carcinogen, or by labelling it "negative" when it
really is a carcinogen.
There are no reasons to assume that false-
negative results of carcinogenicity tests are more
or less frequent than false-positive ones. Labeling
as "carcinogen" a substance that gave rise to in-
creased incidence of tumors requires the develop-
ment of a biological rationale of a causal relation-
ship. Similarly, to dismiss all compounds that did
not induce tumors in one or two mouse and rat ex-
periments as noncarcinogenic is sure to lead to er-
rors.
Experimental procedures that use even large
numbers of animals are likely to detect only strong
carcinogens. When negative results are obtained in
such bioassays, it is not certain that the agent tested
is unequivocally safe, but our personal level of
confidence is probably higher. Therefore, we must
accept and use possibly fallible measures of es-
timating hazard to man. To make these measures
less fallible leads to Principles 3 and 4.
Principle 3
The exposure of experimental animals to toxic
agents in high doses is a necessary and valid
method of discovering possible carcinogenic
hazards in man. The most commonly expressed
objection to regulatory decisions based on car-
cinogenesis observed in animal experiments is that
the high dosages to which animals are exposed have
no relevance to human risks. In general, dosages
that are high in relation to expected human expo-
sures must be given because in model experimental
systems, we have no choice but to use few animals
in comparison with the number ofhumans exposed.
An incidence ofcancer ofabout 10% in a group of
experimental animals represents a lower limit of re-
producibility; 10% of a human population is very
high. For example, an incidence as low as 0.01%
would represent 1000 people in a total population of
10 million and might be considered unacceptably
high even in the face of sizable benefits. To detect
such a low incidence in experimental animals di-
rectly would require hundreds of thousands of ani-
mals. For this reason, we have no choice but to give
large doses to relatively small experimental groups
and then use biologically reasonable models in ex-
trapolating the results to estimate risk at low doses.
Several models for making such calculations have
been used. We think that the best method available
to us today is to assume no threshold and a direct
proportionality between the size ofthe dose and the
incidence of tumors. This model is a conservative,
public-health-oriented approach, but even it could
underestimate risks. A human lifetime is some 35
times that ofa mouse, and there is evidence that the
risk of cancer increases rapidly with the length of
exposure. Moreover, experimental assays are con-
ducted under controlled dietary and environmental
conditions with genetically homogeneous animals,
whereas humans live under diverse conditions, are
genetically heterogeneous, and are likely to include
subpopulations of unusual susceptibility and un-
usual resistance.
Direct application of the linear, no-threshold
model does not take into consideration species dif-
ferences in susceptibility. For example,
,8-naphthylamine is well established as a human car-
cinogen on the basis ofepidemiologic studies ofoc-
cupationally exposed humans, whereas experi-
ments have not shown it to be carcinogenic, for
example, in the hamster, which is relatively resis-
tant. Ifthe hamster data were used to extrapolate to
man, risk would be grossly understated. A conser-
vative procedure would require that we use the
most sensitive species to extrapolate to humans,
recognizing that not all substances that cause a
given incidence of cancer in the rat (or some other
animal) are equally carcinogenic for man. This
means that chronic-toxicity studies, which are im-
perfect assay systems for carcinogenicity testing,
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sessment ofrisk. How other data can be used, how-
ever, is not clear.
Principle 4
Material should be assessed in terms of human
risk, rather than as "safe" or "unsafe." The cur-
rent experimental techniques do not allow us to es-
tablish safe doses of materials shown to be carcino-
gens in animal testing, but with the help ofstatistical
methods we may be able to estimate a reasonable
upper limit ofrisk to human populations, ifwe have
data to estimate population exposure, an appropri-
ate and reproducible assay in animals, and satis-
factory statistical methods. Some important limita-
tions must be recognized. First, no single generally
applicable procedure can be recommended for
testing all toxic agents. The well-informed expert
investigators will have to design appropriate assays
recognizing that they will always be subject to the
scrutiny of their peers. If substances that affect
large populations are found to be carcinogenic,
broad scope experiments may have to be con-
ducted, to obtain more detailed information on their
possible effects in humans. As a pragmatic
guideline, it has been suggested that a potential car-
cinogen be tested in at least two species, such as the
mouse and the rat, in strains ofanimals that have a
low incidence of spontaneous tumors under the
conditions of the test. It may be necessary to in-
clude "positive" controls, with knowncarcinogens,
underthe same conditions usedforthe testanimals.
Experiments should be conducted over as much
as possible of the lifetime of the experimental ani-
mal. The highest dose should be the maximum that
is tolerated without shortening the lifespan through
causes other than cancer. Every animal, whether it
dies during the exposure period or is sacrificed at
the end of the experiment, should be examined
grossly and microscopically, and all toxic effects
(not only cancer) should be noted.
Models for Extrapolation
Several mathematical models for extrapolation
have been proposed. To be meaningful, they must
relate to biological theories of carcinogenesis.
There is no dearth of quantitative theories of car-
cinogenesis that relate the frequency of detectable
tumors to the intensity of exposure to the carcino-
gen. The purposes of these theories are twofold: to
elucidate the mode of action of the carcinogen and
the nature ofthe neoplastic change and to estimate,
from animal experimentation, the risk to human
populations exposed to environmental concentra-
tions of the carcinogen.
One of the earliest quantitative theories was that
of Iverson and Arley (1, 2). Their model was basi-
cally a one-step transition process occurring in a
single cell. A cell starts out being "normal" and has
some positive probability of being transformed to a
cancer cell. Iverson and Arley assumed that this
transition probability was a linear function of the
amount of the carcinogen, the intercept of this
linear function representing the background or
spontaneous transition probability, as would obtain
ifnone of the carcinogen were present. After trans-
ition to a cancer cell, Iverson and Arley assumed,
the growth of the clone could be represented by a
pure birth process with a birth rate independent of
the initial amount ofthe carcinogen. The clone was
assumed to become a detectable tumor when it
reached a given size. This model is commonly re-
ferred to as the one-hit model and implies that the
expected number of tumors within a lifetime will
depend only on the total dose and not on the pattern
of exposure. The mathematical forms of a wide
class ofhit-theory models were given by Turner (3)
who developed the mathematical theory between
the "hits" of an agent and the critical targets. He
also discussed extensions that include both biologic
variation in the probability of a hit and variation in
the number of critical targets.
Nordling (4) and Stocks (5) each carried the
Iverson-Arley model forward in proposing models
in which a single cell can generate atumoronly after
it has undergone more than one change or mutation;
these could be termed multievent theories of car-
cinogenesis. They assumed that the probabilities of
transition from one state to the next within some
time frame were the same and were proportional to
both time and the concentration of the carcinogen.
Like Iverson and Arley, Nordling and Stocks as-
sumed that the growth time of the tumor after the
last event had occurred was either independent of
the carcinogen or showed a negligible dependence
on dose. When the number of necessary changes is
about 6 or 7, this model yields age-specific cancer
incidence rates that are proportional to the fifth or
sixth power of age and in this respect the model is
consistent with human incidence data. However,
the model also predicts that cancer incidence is
proportional to the same high powers of the con-
centration of the carcinogen; this is not in agree-
ment with the results ofhuman and animal data. To
avoid this discrepancy, Armitage and Doll (6, 7)
modified the theory of Nordling and Stocks by as-
suming that the probabilities of transition between
events were not all equal. They also assumed that
only some of the transitional events depended on
the carcinogen and that the remainder had a proba-
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level of the carcinogen in question. With this mod-
ification, the model became consistent with both
human and animal data that showed tumor inci-
dence as related to either dose or the square of
dose, but not higher powers.
In the dichotomous-response situation, the multi-
event theory of carcinogenesis proposed by Armi-
tage and Doll (7) leads to a mathematical model that
relates the probability ofresponse P(d) at the dose d
by
P(d) = 1 -exp{- (Xo +Xld+2d2+.. . + XAdk)}
where k represents the number of transitional
events in the carcinogenic process that are related
to the carcinogen under test and X0, X1, X2, * * ., Ak
are unknown nonnegative parameters. As with the
other "linear-at-low-dose" models, for small
enough values ofthe exposure d, this dose-induced
response rate will be approximately equal to Xld
(assuming that A,o is the "background" rate.)
Therefore, in extrapolating from high dose levels to
low doses, the risk attributable to the carcinogen,
after correcting for background, will depend on the
magnitude of the linear coefficient X1.
In practice, when this model is applied to the
problem of risk estimation, the model is to be fit to
the experimental data by some such procedure as
maximum likelihood. A point estimate of the at-
tributable risk may be obtained from the model with
the estimated parameter, but, to incorporate the
vagaries ofrandom sampling, it would be prudent to
include the upper statistical confidence limit on this
risk estimate.
It should be noted that the theories of Nordling,
Stocks, and Armitage and Doll are based on the
concept that carcinogenesis has a single-cell origin,
whereas a theory proposed by Fisher and Holloman
(8) is multicellular in concept. They proposed that a
tissue of N cells must contain at least K cells that
have undergone some transformation, for a tumor
to occur in the tissue. This theoretical approach
leads to a model very similar in form to the multi-
event model. Other multievent theories have been
proposed that incorporate the concepts ofcell death
or loss ofability to divide (9) and modifications that
permit cells in intermediate stages to grow more
rapidly than normal (10). In part, the approach by
Burch also includes such concepts as repair-the
death of a precancer cell being equivalent to the
repair of that cell, in the sense that having died or
having been repaired the cell will not go on to de-
velop as a cancer.
Crump et al. (11) discussed many ofthese models
of carcinogenesis from the viewpoint of low-dose
kinetics. They made two basic assumptions: that
the cancer process is single-cell in origin possibly
with multiple steps between initiation and complete
alteration, and that the growth period of the com-
pletely altered cell is basically independent of the
initiating dose. For direct carcinogenic processes,
in which the agent or its metabolite acts at the cel-
lular level to produce an irreversible change, they
concluded that most models of carcinogenesis will
be linear for low doses. In addition, they showed
that, if it can be assumed that the environment
contains carcinogens that act in conjunction with
the tested agent, then all the models thus far pro-
posed will be linear for low doses.
Dose Considerations
In all these theories, the emphasis is mainly on
the stochastic nature of the changes involved in the
carcinogenesis process. The role played by the car-
cinogen is considered to a much lesser degree. It is
commonly assumed that the transitional events in
the process attributable to the carcinogen occur
with probabilities proportional to the exposure.
This is undoubtedly an oversimplification of the
actual process. The actual exposure is modified by
absorption, distribution, metabolism, and excretion
of the chemical substance, and the effective expo-
sure should probably be the actual concentration of
the carcinogen at and within the target cells. Other
factors that may affect delivery ofthe carcinogen to
intracellular compartments are membrane permea-
bility and enzyme binding. Therefore, the "effec-
tive dose" may well be some complex function of
the actual exposure and the biochemical and
physiologic characteristics of the host. Most of
these mathematical models incorporate the dose as
it is actually administered in animal experiments or
human exposure. The function relating adminis-
tered dose to "effective dose," if it is not a simple
case of proportionality, can have a profound effect
on the dose-response relationship. As a simple
example, consider a linear model relating dose (ef-
fective dose) to response. If the effective dose is
proportional to the administered dose, then a linear
model obtains for administered dose versus re-
sponse. If the dose relationship is concave, which
would obtain ifthe incremental increase in effective
dose decreases with higher doses, then the relation-
ship between administered dose and response
would also be concave. Thus, the various dose-
response curves that have been observed may not
be indicative of different carcinogenic processes
once the agent has reached the target cell, but rather
may indicate different functions relating to how an
administered dose becomes an effective dose. This
February 1978 119problem will probably relate more to chemical car-
cinogenesis, as opposed to radiation induced
cancer.
Repair, Destruction, and
Threshold
Even if a normal cell has been transformed to
some intermediate stage in the carcinogenic pro-
cess, this would not necessarily mean that cancer
must occur. Cell repair or recovery or some other
response from the immume mechanisms (i.e., cell
destruction) may be sufficient to stop or reverse the
process before the self-perpetuating stage is
reached. Inaddition, the death ofthese transformed
cells may occur before the process has a chance to
continue toward the eventual cancer. This is one of
the major arguments in favor of the existence of a
threshold. However, if there is some probability
that these recovery or destruction mechanisms will
not complete their role before the occurrence of
another event or transformation, then this type of
threshold will not exist.
Thresholds may be considered from two view-
points: an "actual" threshold, which is an exposure
below which any carcinogenic response attributable
to the specific agent is impossible; and a "practi-
cal" threshold, which is an exposure below which
an attributable carcinogenic response is highly un-
likely. In discussing carcinogenic thresholds,
Mantel (12) has argued that whether "actual"
thresholds exist is of less importance than "practi-
cal" thresholds when estimating human risk. He
has suggested procedures for extrapolating the re-
sults of animal experiments performed at necessar-
ily high exposures to the lower exposures of hu-
mans. He and Bryan (13) stated that arisk ofcancer
of 1 in 108 could be thought of as a "virtually safe"
level and that efforts should be made to estimate
exposures that would produce no more than this
risk. Using mathematical models that relate the la-
tency period (time between initiation of exposure
and appearance of cancer) to the exposure, Jones
(14) suggested that a "practical" threshold could be
defined as an exposure for which the latency period
is beyond the normal lifespan.
Experimental or observational evidence of the
existence of a threshold is usually presented in the
form of a dose-response graph in which the per-
centage of animals with tumors or the average
number of tumors per animal is plotted against the
dose of the carcinogen. Either the existence of
doses not leading to an increase in tumor incidence
over controls or the extrapolation ofsuch curves to
low doses that apparently would result in no tumor
increase is cited as an indication ofthe existence of
a threshold below which no response is possible.
This type of evidence is an exercise in self-
deception.
First, as noted earlier, the observation of no
positive responses does not guarantee that the
probability of response is actually zero. From a
statistical viewpoint, zero responders out of a
population of size N is consistent at the 5% signifi-
cance level with an actual response probability be-
tween zero and approximately 3/N (e.g., when N =
100 and zero responders are observed, the true
probability of response may be as high as 3%).
Second, when an observed plot of dose against
tumors is extrapolated downward to produce a no-
effect dose, it is assumed that the observed dose-
response relationship, usually linear, will obtain
throughout the entire spectrum of doses and that
one threshold exists for the entire population at
risk. The assumption of linearity throughout the
entire dose spectrum can easily lead to erroneous
conclusions. For example, consider the true dose-
response relationship shown by the dashed curve
in Figure 1. This curve is convex, which would be
consistent with a multievent theory of car-
cinogenesis in which more than one event is af-
fected by the carcinogenic agent. This type of con-
vex dose-response relationship, when sampled in
an animal experiment over only a part of the dose
range, could be thought to imply the existence of a
threshold if simple linear extrapolation is used. If
the animal experiment is performed at doses be-
tween A and B, one could conclude that a threshold
exists at dose di, if the experiment is performed at
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Idoses between B and C, the conclusion could be a
higher threshold at dose d2. In fact, for convex
dose-response curves, if the experiment is per-
formed over any range ofdoses that appears to pro-
duce linearity between dose and response, then
simple linear extrapolation will always imply the
existence of a threshold.
In addition, the assumption of one threshold is
unrealistic. It is much more likely that, ifthresholds
do exist, not all members ofthe population have the
same one. The human population is diverse and
genetically heterogeneous, and is exposed in differ-
ent degrees to a large variety of toxic agents. Many
different disorders may affect the frequency of mu-
tational events in specific tissues. Disorders
characterized by chromosomal instability have been
found to be predisposed to malignancy. Patients
with xeroderma pigmentosum are highly susceptible
to ultraviolet-induced skin cancer, and it has been
found that they have deficient DNA repair
mechanisms (15). In Bloom's syndrome, there is an
immune deficiency and an increased risk of
leukemia and cancer of the colon (16). Although
there have been problems in reproducing the early
results, there is some evidence that the amount of
an enzyme, aryl hydrocarbon hydroxylase (AHH),
which is genetically controlled, may determine the
susceptibility to lung cancer from cigarette smoking
(17). This system may provide a model in which the
risk of mutation and subsequent malignancy after
exposure to an environmental carcinogen may be
genetically determined. If malignancy is the result
of a series of mutational events, then there must be
subpopulations at various degrees of risks or with
various thresholds for the carcinogenic agent.
Therefore, the search for thresholds should not be a
search for one specific no-effect dose applicable to
all members of the population at risk: rather, the
problem is to find many thresholds for each of the
subgroups in the population.
This variability in thresholds or susceptibility to
carcinogenic agents has been shown by Mantel (18)
to induce an increased convexity in dose-response
curves at low doses. They demonstrated that a
linear dose-response curve with a fixed threshold
will become convex at low exposures, if the indi-
vidual thresholds are allowed to vary. Therefore,
the extrapolation of observed dose-response
curves, when the individual thresholds actually
vary in the population, will, at best, lead simply to
the average threshold of the population at risk. An
estimate of the average threshold will have little
practical utility, because many members of the
population will have individual thresholds below
this value. In addition, if we are willing to assume
thatthreshold variability is the likely state in nature,
then from a statistical viewpoint it is practically im-
possible to distinguish between mathematical mod-
els that hypothesize different thresholds and mul-
tievent models that hypothesize no thresholds, be-
cause the shapes of the two models can be very
similar, and in some cases identical. For example, a
one-hit dose-response model with a threshold may
be written as,
P(d/X) =I - exp{ -a (d - X)}
d <X
d > A
where P(d/X) represents the dose-induced response
rate at a dose level d and X is the threshold below
which no response can occur. Ifwe assume that the
population consists of individuals with different
thresholds and that these thresholds vary according
to some probability distribution F(X), then the
variable-threshold model is simply the convolution
of P(d/X) with F(X),
P(d) JP(d/X)dF(X)
If, for computational simplicity, we choose F(A) to
be an exponential probability distribution, then this
variable-threshold model takes the mathematical
form,
P(d) exI {-ad} -(a/a8) exp
The interesting aspect of this particular mathemati-
cal model is that, as the ratio a/,8 approaches unity,
the model becomes
P(d) = I - (I - ad)e-a
which is the mathematical form of a two-hit model
for dose response.
Discrimination among these models on the basis
of animal experiments is often impossible. These
three models were fitted to datafrom an experiment
by Terracini et al. (19) in which dietary concentra-
tion of dimethylnitrosamine (DMN) of 0-20 ppm
were fed to female rats. The experiment was con-
tinued for 120 weeks, and the appearance of liver
tumors was the response variable. The data are
shown in Table 1.
Table 1. Response to dimethylnitrosamine (DMN).
DMN in Number responders Response
diet, ppm number at risk rate, %
0 0/20 0.0
2 0/18 0.0
5 4/62 6.5
10 2/5 40
20 15/23 65
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els, in addition to the two-hit model, all fit these
data equally well. There is no statistical basis on
which to prefer one over the others. Experimental
results like these, although appearing to give evi-
dence ofa threshold, will provide no statistical evi-
dence either in favor ofor opposed to the existence
ofsuch thresholds. Therefore, statistical analysis of
standard animal carcinogenicity experiments is not
now, and probably will never be, in a position to
resolve the threshold question. There are too many
"biologically reasonable" mathematical models,
both implying and denying the existence of
thresholds, that will fit the observed results.
The quantitative theories of carcinogenesis that
have been proposed are all stochastic. They con-
sider the probabilistic chances ofthe occurrence of
some series of events. If one is willing to assume
that these events have transition probabilities that
can be affected by the carcinogen (no matter how
small the concentration), that the systems of dis-
tribution and metabolism have some chance of al-
lowing some amount of the carcinogenic agent to
reach the target cells (no matter how small the
chance or the amount), and that the repair, destruc-
tion and recovery systems may not do a perfectjob
(no matter how small the chance that this will hap-
pen), then there will be no exposure that will have a
zero probability of leading to a cancer.
In addition, when considering the possibility of
carcinogenic thresholds, one should keep in mind
that no agent has been found to induce a type of
cancer that had not been previously described. It is
possible, perhaps even likely, that many car-
cinogenic agents act by the same mechanism on the
same target cells. This would imply that, inasmuch
as there are many carcinogenic agents in our every-
day environment, some additional carcinogen could
act in a simple additive manner and thus that any
exposure would simply be added to the background.
This means that, for a population already being ex-
posed to carcinogenic agents, any additional car-
cinogen would simply increase the expected tumor
incidence in a continuous manner, no matter how
low the exposure to the additional agent. Therefore,
despite all the complexities of the mechanisms of
chemical carcinogenesis, because of genetic varia-
tion among members of the population at risk and
because statistical analysis cannot resolve the
question one way or the other, the search for an
"actual" carcinogenic threshold is probably fruit-
less, and any human exposure to a carcinogen
should be considered to be associated with some
risk, no matter how small that risk may be. The
current mathematical models thatrelate exposure to
attributable risk are, at best, extremely crude tools.
Much work needs to be done in refining these
theories (20).
The material presented here was developed largely from a re-
port of the National Research Council, National Academy of
Sciences' Safe Water Committee (1977), of which the senior au-
thor was a member. Modifications have been made to make this
report more germane to issues ofairpollution, urban hazards and
energy production. Scientists who contributed to portions ofthe
NAS report from which this paper is derived included Drs.
David Rall, David Hoel, Charles Brown, Sheldon Murphy,
J. Martin Brown, Edwin Lennette.
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